Future of clinical trials for pulmonary hypertension

Circulation

Volumn 123, Issue 25, 2011, Pages 2919-2921

  Rich, Stuart ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

clinical trials; Editorial; hypertension pulmonary; pulmonary heart disease

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; SEROTONIN ANTAGONIST; SIMVASTATIN;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EDITORIAL; ENDOTHELIUM CELL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART CATHETERIZATION; HUMAN; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SAMPLE SIZE; THROMBOCYTE ACTIVATION; TREATMENT RESPONSE;

ASPIRIN; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT OUTCOME; WALKING;

EID: 79960018739     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.037762     Document Type: Editorial

References (23)

1. Barst R, Rubin L, Long W, McGoon M, Rich S, Badesch D, Groves B, Tapson V, Bourge R, Brundage B, Koerner S, Langleben D, Keller C, Murali S, Uretsky B, Clayton L, Jobsis M, Blackburn S, Shortino D, Crow J. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301. (Pubitemid 26033085)
2. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431. (Pubitemid 44454562)
3. Macchia A, Marchioli R, Tognoni G, Scarano M, Marfisi R, Tavazzi L, Rich S. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2009; 159:245-257.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122:156-163.
5. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010;138:1234-1239.
6. Achcar RO, Yung GL, Saffer H, Cool CD, Voelkel NF, Yi ES. Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension. Eur J Med Res. 2006;11:203-207.
7. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. 2010;121:2045-2066.
8. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, Tracy RP, Palevsky HI, Hassoun PM, Girgis RE; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011;123:2985-2993.
9. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032.
10. Utilization of a human lung tissue resource for vascular research (R03). Last updated October 12, 2010. http://grants.nih.gov/grants/guide/rfafiles/ RFA-HL-11-032.html. Accessed May 15, 2011.
11. Moreno-Vinasco L, Garcia JG. Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension. Adv Exp Med Biol. 2010;661:419-434.
12. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005;111:2812-2819. (Pubitemid 40791554)
13. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002;105:244-250. (Pubitemid 34084326)
14. Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, Zhu JH, Chen JZ. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 2007;49: 1566-1571.
15. New resource for drug developers: The Rare Disease Repurposing Database. Last updated September 2, 2010. http://www.fda. gov/ForIndustry/ DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/ucm216147.htm. Accessed May 15, 2011.
16. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157. (Pubitemid 41653106)
17. The Critical Path Initiative. Last updated April 29, 2011. http:// www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ default.htm. Accessed May 15, 2011.
18. Adaptive design clinical trials for drugs and biologics. Last updated February 1, 2010. http://www.fda.gov/downloads/Drugs/GuidanceCom plianceRegulatoryInformation/Guidances/UCM201790.pdf. Accessed May 15, 2011.
19. Critical Path Institute-Coalition Against Major Diseases. Last updated June 11, 2010. http://www.c-path.org/CAMD.cfm. Accessed May 15, 2011.
20. The Biomarker Consortium. Last updated November 1, 2010. http:// www.fda.gov/AboutFDA/PartnershipsCollaborations/PublicPrivatePart nershipProgram/ucm231115.htm. Accessed May 15, 2011.
21. The codevelopment of two or more unmarketed investigational drugs for use in combination. Last updated December 16, 2010. Available at http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ ucm237264.htm. Accessed May 15, 2011.
22. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
23. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992;19:1060-1064.